Biopharma industry sentiment on regulatory changes
Discussed in 1 analyzed podcast episode across 1 show
Discussed On
Episodes
BioSpace · May 13, 2026
Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay
FDA Commissioner leadership transition and removalRegulatory uncertainty and HHS agency turnoverCommissioner's National Priority Review voucher programRare disease drug approval inconsistenciesCBER and CDER leadership vacancies
View Analysis